DMPK Talent Market Report 2026: What Hiring Leaders Should Know

Based on Drug Metabolism and Pharmacokinetics (DMPK) openings tracked and analyzed by Hughes & Associates during the first half of 2026, several notable workforce trends are emerging across the pharmaceutical and biotechnology industries.
Our review included scientific and leadership positions ranging from Scientist to Vice President and Head of Function across both established pharmaceutical companies and clinical-stage biotechnology organizations. The analysis examined hiring demand, compensation disclosures, work models, therapeutic modalities, technical capability requirements, and leadership expectations within the DMPK function.
These observations provide a real-time view of how organizations are structuring teams, prioritizing capabilities, and competing for talent in an increasingly strategic area of drug discovery and development.
Talent Demand Trends
Leadership Hiring Continues to Drive Demand
The DMPK market continues to show strong demand for experienced scientific leadership. While opportunities were available across the full career spectrum, more than half of the openings reviewed were at the Associate Director level or above.
| Position Level | Observed Frequency |
|---|---|
| Scientist / Senior Scientist / Principal Scientist | 42.5% |
| Associate Director / Director / Senior Director | 37.5% |
| Executive Director / Vice President / Head of Function | 20.0% |
Organizations increasingly appear to be seeking professionals capable of influencing discovery strategy, leading multidisciplinary project teams, and integrating DMPK into broader portfolio decisions.
Biotechnology Continues to Drive Hiring Activity
Biotechnology companies represented the majority of hiring activity throughout the year.
| Company Type | Observed Frequency |
|---|---|
| Biotechnology & Specialty Biopharma | 82.5% |
| Large Pharmaceutical Companies | 17.5% |
Many biotechnology organizations are expanding internal DMPK capabilities as programs advance from discovery through IND-enabling studies and into early clinical development. Several were also recruiting senior leaders to establish or grow DMPK functions while coordinating extensive external collaborations.
Oncology Remains the Most Active Therapeutic Area
Among the openings reviewed, oncology emerged as the most frequently represented therapeutic area.
Other commonly represented areas included:
- Immunology & Inflammation
- Neuroscience / CNS
- Rare Disease
- Gastrointestinal Disease
- Hematology
- Cardiometabolic Disease
- Viral & Liver Disease
- Ophthalmology
The continued growth of targeted therapies and precision medicine appears to be sustaining demand for DMPK expertise across increasingly complex drug development programs.
Drug Modality Trends
Multi-Modality Expertise Continues to Expand
Although small molecules remain the dominant therapeutic modality, employers are increasingly seeking DMPK professionals capable of supporting diverse platforms.
| Therapeutic Modality | Observed Frequency |
|---|---|
| Small Molecules | 67.5% |
| Biologics / Large Molecules | 40.0% |
| Peptides / Miniproteins | 17.5% |
| Oligonucleotides / RNA Therapeutics | 15.0% |
| Targeted Protein Degraders (TPD/PROTACs) | 12.5% |
| Antibody-Drug Conjugates (ADCs) | 12.5% |
| Gene Therapy | 7.5% |
| Radiopharmaceuticals | 5.0% |
Percentages exceed 100% because many positions supported multiple therapeutic modalities.
Compared with just a few years ago, DMPK professionals are increasingly expected to apply the same scientific principles across multiple drug platforms, each with unique ADME, bioanalytical, and translational considerations.
Compensation Intelligence
Compensation remains highly competitive across the DMPK market.
Based on salary disclosures included within the reviewed postings:
| Position Level | Typical Salary Range |
|---|---|
| Scientist – Principal Scientist | $90K–$260K |
| Associate Director – Senior Director | $164K–$338K |
| Executive Director / Vice President / Head | $208K–$443K |
Most organizations also referenced annual bonus programs, equity participation, long-term incentive plans, and comprehensive benefits packages, particularly among biotechnology companies.
Work Setup Trends
Hybrid Work Remains Common, but Onsite Roles Continue to Be Important
Among positions that specified work arrangements, onsite work remained more common than seen in many other drug development disciplines.
| Work Arrangement | Observed Frequency |
|---|---|
| Onsite | 57.1% |
| Hybrid | 28.6% |
| Remote | 14.3% |
Based only on positions that explicitly disclosed work arrangements.
Unlike many quantitative disciplines, DMPK continues to maintain a significant laboratory and cross-functional presence, contributing to the continued demand for onsite collaboration.
Scientific Capabilities in Highest Demand
Across the 40 openings reviewed, several capabilities appeared consistently.
| Capability | Observed Frequency |
|---|---|
| Pharmacokinetics | 100% |
| Cross-Functional Collaboration | 100% |
| ADME Expertise | 87.5% |
| Regulatory Support | 87.5% |
| PK / PK-PD Modeling | 80.0% |
| Human PK & First-in-Human Dose Prediction | 72.5% |
| CRO & External Partner Management | 70.0% |
| Bioanalysis & Data Interpretation | 45.0% |
| PBPK Modeling | 20.0% |
| AI / Machine Learning / AI-enabled Workflows | 17.5% |
ADME Expertise Remains Foundational
Designing and interpreting ADME studies continues to form the foundation of modern DMPK practice.
Frequently requested expertise included:
- Drug metabolism
- Plasma protein binding
- Drug-drug interaction assessment
- Metabolite identification
- Biotransformation
- Tissue distribution
- Permeability
- In vitro and in vivo ADME studies
Organizations consistently sought candidates capable of translating ADME findings into meaningful project decisions rather than simply generating experimental data.
PK/PD Modeling Continues to Grow in Importance
PK and PK/PD modeling appeared across Scientist, Director, and executive-level roles.
Employers increasingly expect DMPK professionals to contribute to:
- Human PK prediction
- Dose projection
- Exposure-response analysis
- PBPK modeling
- Mechanistic PK/PD modeling
- Clinical translation
- Sensitivity analyses
- Virtual population simulations
Model-informed decision-making is becoming an increasingly common expectation across the broader DMPK function.
Translational Drug Development Is Now Central to DMPK
Many organizations now expect DMPK scientists to contribute throughout the drug development lifecycle.
Frequently referenced responsibilities included:
- Candidate selection
- Human PK prediction
- First-in-human dose projection
- Clinical risk assessment
- Therapeutic index evaluation
- Dose optimization
- Translational strategy
The findings suggest that DMPK has evolved from a supporting discipline into an integral component of program strategy.
Regulatory Responsibilities Continue to Expand
Regulatory support appeared in 87.5% of the reviewed positions.
Frequently referenced activities included:
- INDs
- CTAs
- NDAs
- BLAs
- Investigator Brochures
- Common Technical Documents
- Regulatory briefing packages
- Responses to health authority questions
Senior-level positions frequently included direct interaction with regulatory agencies and responsibility for ensuring scientifically robust nonclinical packages.
CRO & External Partner Management
Management of CROs and external scientific partners appeared in 70.0% of the positions reviewed.
Common responsibilities included:
- Vendor selection
- Protocol development
- Study oversight
- Budget management
- Timeline management
- Scientific review
- Bioanalytical oversight
- Quality assurance
For many biotechnology companies, successful DMPK execution relies heavily on effective management of external scientific partnerships.
Bioanalysis Continues to Play a Critical Role
Bioanalysis remained an important component of many DMPK positions.
Frequently requested experience included:
- LC-MS/MS
- Ligand-binding assays
- Assay development and validation
- Metabolite identification
- Biodistribution studies
- Immunogenicity assessment
- High-resolution mass spectrometry
The integration of bioanalysis with DMPK was particularly evident across biologics, peptide, ADC, radiopharmaceutical, and other emerging therapeutic modalities.
Leadership Expectations Continue to Expand
Today’s DMPK leaders are expected to contribute well beyond traditional ADME and pharmacokinetic responsibilities.
Common expectations included:
Strategic Leadership
- Defining DMPK strategy
- Influencing candidate selection
- Supporting portfolio decisions
- Identifying development risks
- Guiding translational strategy
Matrix Leadership
Frequent collaboration with:
- Medicinal Chemistry
- Pharmacology
- Toxicology
- Clinical Pharmacology
- Translational Medicine
- Regulatory Affairs
- Bioanalysis
- Clinical Development
- CMC
- Modeling & Simulation
Organizational Leadership
Many senior positions also included:
- Building DMPK teams
- Developing scientific talent
- Managing departmental budgets
- Establishing external partnerships
- Scaling internal capabilities
Emerging AI & Technology Signals
Artificial intelligence and digital technologies are beginning to influence DMPK hiring.
Among the reviewed positions, 17.5% referenced AI, machine learning, automation, or digital workflows.
Examples included:
- AI-assisted modeling
- Machine learning
- Predictive ADME platforms
- Automated DMPK workflows
- Digital laboratory technologies
While still emerging, these capabilities are increasingly being incorporated alongside traditional experimental and quantitative approaches.
Key Takeaway
The 2026 DMPK talent market reflects the continued evolution of Drug Metabolism and Pharmacokinetics into a highly strategic function within modern drug discovery and development.
Organizations are increasingly seeking professionals who combine scientific depth in ADME and pharmacokinetics with quantitative modeling, translational thinking, regulatory expertise, and cross-functional leadership.
As therapeutic modalities continue to diversify and development programs become more complex, DMPK professionals are playing an increasingly influential role in candidate selection, dose optimization, clinical translation, and portfolio decision-making.
For hiring managers, HR leaders, and talent acquisition teams, the market continues to favor individuals who can integrate strong scientific expertise with broader strategic and organizational impact.
About Hughes & Associates
Keeping pace with today’s DMPK talent market requires ongoing visibility into hiring trends, organizational priorities, and emerging workforce needs.
At Hughes & Associates, we continuously monitor hiring activity, talent movement, compensation trends, and organizational developments across Clinical Pharmacology, Pharmacometrics, QSP, DMPK, Bioanalysis, and related translational sciences functions.
If your team is evaluating hiring strategy, workforce planning, organizational design, or simply looking to compare notes on what we are seeing across the market, we would be glad to connect for a confidential discussion.
To learn more about Hughes & Associates and our specialized life sciences search capabilities, visit our website: https://www.haallc.com
For additional market insights, industry updates, and talent trends, follow Hughes & Associates on LinkedIn, Instagram, Facebook, and X.
We look forward to continuing the conversation around the evolving DMPK and translational sciences talent landscape.
Read More
Clinical Pharmacology Talent Market Report 2026: What Hiring Leaders Should Know
Biopharma In A More Stable Phase: What It Means for Hiring and Careers in Clinical Pharmacology
Why Clinical Pharmacology Leadership Roles Are So Hard to Fill at the Director-to-Head Level